Cytosorbents' (CTSO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research report report published on Wednesday morning, Benzinga reports. The brokerage currently has a $5.50 price objective on the medical research company’s stock. HC Wainwright also issued estimates for Cytosorbents’ FY2023 earnings at ($0.59) EPS, Q1 2024 earnings at […]

Related Keywords

Chicago ,Illinois ,United States ,Montreal ,Quebec ,Canada ,Germany ,Kathleenp Bloch , ,Renaissance Technologies ,Cytosorbents Corporation ,Raymond James Financial Services Advisors Inc ,Goldman Sachs Group Inc ,Chicago Partners Investment Group ,Free Report ,Get Free Report ,James Financial Services Advisors ,Montreal Can ,Sachs Group ,Cytosorbents Daily ,Cytosorbents ,Nasdaq Ctso ,Ctso ,Medical ,Reiterated Rating ,Hc Wainwright ,